Re: Long-Term Efficacy and Toxicity of Cholinesterase Inhibitors in the Treatment of Alzheimer Disease

Hogan DB . Long-term efficacy and toxicity of cholinesterase inhibitors in the treatment of Alzheimer disease. Can J Psychiatry. 2014;59(12):618–623.

Gauthier S Patterson C Chertkow H , Recommendations of the 4th Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (CCCDTD4). Can Geriatr J. 2012;15:120–126.

Maxwell CJ Stock K Seitz D , Persistence and adherence with dementia pharmacotherapy: Relevance of patient, provider, and system factors. Can J Psychiatry. 2014;59:624–631.

Amuah JE Hogan DB Eliasziw M , Persistence with cholinesterase inhibitor therapy in a population-based cohort of patients with Alzheimer's disease. Pharmacoepidemiol Drug Saf. 2010;19:670–679.

Health Canada. Health Canada Advisory: Reminyl ER (galantamine hydrobromide) – new safety information regarding the risk of serious skin reactions. Ottawa (ON): Health Canada; 2014.

Health Canada. Summary Safety Review – Aricept (donepezil) – risk of rhabdomyolysis and neuroleptic malignant syndrome. Ottawa (ON): Health Canada; 2015.